Sugi Predict

Sugi Predict / Compounds / SCHEMBL4608765

SCHEMBL4608765

SCHEMBL4608765

N#Cc1ccc(O)c2cccnc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.49
▸ MAPT P10636 4/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ KDM4E B2RXH2 8/20 0.47
▸ L3MBTL1 Q9Y468 5/20 0.47
▸ HSP90AA1 P07900 4/20 0.47
▸ HTT P42858 3/20 0.47
▸ IDO1 P14902 2/20 0.47
▸ BRD4 O60885 2/20 0.47
▸ METAP2 P50579 2/20 0.47
▸ MPI P34949 1/20 0.47
▸ METAP1 P53582 1/20 0.47
▸ HSP90AB1 P08238 1/20 0.47
▸ PSMB5 P28074 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ NPC1 O15118 4/20 0.46
▸ RAB9A P51151 4/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1187421 0.86 HSP90AA1 (0.61) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4012471 0.86 KDM4E (0.42) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL4301084 0.84 HSP90AA1 (0.59) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL29992757 0.80 LRRK2 (0.46) LMNAL3MBTL1HSP90AA1NPC1LRRK2
SCHEMBL29826020 0.79 L3MBTL1 (0.56) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL20554409 0.79 L3MBTL1 (0.56) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL7323209 0.79 KDM4E (0.56) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL29871808 0.79 KMT2A (0.54) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL3194949 0.79 HSP90AA1 (0.56) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL3142508 0.79 PSMD14 (0.56) LMNAMAPTMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135173-A1 NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2023-05-04 — — US disclosed
US-11535606-B2 Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof ACCUTAR BIOTECHNOLOGY INC. (US) 2022-12-27 — — US disclosed
WO-2021061204-A1 NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2021-04-01 — — WO disclosed
US-20210087171-A1 NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES WITH ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2021-03-25 — — US disclosed
EP-1948615-B1 Pyrazole derivatives useful for the treatment of gynaecological diseases PFIZER LTD (GB) 2011-12-14 — — EP disclosed
EP-1948615-B1 Pyrazole derivatives useful for the treatment of gynaecological diseases PFIZER LTD (GB) 2011-12-14 — — EP disclosed
CN-101304974-A Pyrazole derivatives and their medical use PFIZER LTD (GB) 2008-11-12 — — CN disclosed
US-7425569-B2 1H-pyrazoles useful in therapy PFIZER INC (US) 2008-09-16 — — US disclosed
US-7425569-B2 1H-pyrazoles useful in therapy PFIZER INC (US) 2008-09-16 — — US disclosed
US-7425569-B2 1H-pyrazoles useful in therapy PFIZER INC (US) 2008-09-16 — — US disclosed
US-20080085919-A1 1H-Pyrazoles Useful In Therapy BRADLEY PAUL A 2008-04-10 — — US disclosed
US-20080085919-A1 1H-Pyrazoles Useful In Therapy BRADLEY PAUL A 2008-04-10 — — US disclosed
US-7309712-B2 1H-pyrazoles useful in therapy PFIZER LIMITED (GB) 2007-12-18 — — US disclosed
US-7309712-B2 1H-pyrazoles useful in therapy PFIZER LIMITED (GB) 2007-12-18 — — US disclosed
US-7309712-B2 1H-pyrazoles useful in therapy PFIZER LIMITED (GB) 2007-12-18 — — US disclosed
WO-2007054770-A2 PYRAZOLE DERIVATIVES AND THEIR MEDICAL USE PFIZER LIMITED (GB) 2007-05-18 — — WO disclosed
WO-2007054770-A2 PYRAZOLE DERIVATIVES AND THEIR MEDICAL USE PFIZER LIMITED (GB) 2007-05-18 — — WO disclosed
US-20070105909-A1 Compounds useful in therapy PFIZER INC. 2007-05-10 — — US disclosed
US-20070105909-A1 Compounds useful in therapy PFIZER INC. 2007-05-10 — — US disclosed
US-20070105909-A1 Compounds useful in therapy PFIZER INC. 2007-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105909-A1 Compounds useful in therapy GNRHR, OPRK1, CBR3 LMNA 752/4885MAPT 4865/4885MEN1 989/4885
US-20210087171-A1 NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES WITH ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF AR, NR5A1, ESRRA LMNA 1762/4885MAPT 4301/4885MEN1 3121/4885
US-11535606-B2 Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof AR, NR5A1, ESRRA LMNA 1733/4885MAPT 4286/4885MEN1 2804/4885
US-20080085919-A1 1H-Pyrazoles Useful In Therapy CBR3, GNRHR, RXFP3 LMNA 1103/4885MAPT 4868/4885MEN1 1373/4885
US-20230135173-A1 NOVEL SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF AR, NR5A1, ESRRA LMNA 1590/4885MAPT 4303/4885MEN1 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.